137 related articles for article (PubMed ID: 12077887)
1. [Experiences of the drug approval processes in the European Union].
Pasanen M; Toivonen M
Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
[No Abstract] [Full Text] [Related]
2. Drug evaluation and approval process in the European Union.
San Miguel MT; Vargas E
Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
[No Abstract] [Full Text] [Related]
3. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
4. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
5. Fractured European market undermines biosimilar launches.
Moran N
Nat Biotechnol; 2008 Jan; 26(1):5-6. PubMed ID: 18183000
[No Abstract] [Full Text] [Related]
6. Drug regulation in the European Union.
Griffin JP
Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):179-206. PubMed ID: 11059359
[No Abstract] [Full Text] [Related]
7. [Does collaboration inside the European Union improve Finnish drug safety?].
Palva E
Duodecim; 2000; 116(24):2810-1. PubMed ID: 12077885
[No Abstract] [Full Text] [Related]
8. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
9. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
10. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
11. The European Medicines Agency's plans for sharing data from clinical trials.
Groves T; Godlee F
BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
[No Abstract] [Full Text] [Related]
12. The end of the beginning?
Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
[No Abstract] [Full Text] [Related]
13. Drugs approval process gets speed treatment.
Klarreich E
Nature; 2001 Jul; 412(6845):364. PubMed ID: 11473269
[No Abstract] [Full Text] [Related]
14. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
15. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
16. [Marketing of pediatric drugs].
Pabst JY
Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
[No Abstract] [Full Text] [Related]
17. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
18. European Commission wants drug companies to test products for use in children.
Watson R
BMJ; 2004 Oct; 329(7470):818. PubMed ID: 15472249
[No Abstract] [Full Text] [Related]
19. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
[No Abstract] [Full Text] [Related]
20. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
